No

Antineoplastic Agent, Antimetabolite

Treatment of gastrointestinal adenocarcinoma metastatic to the liver

D

Poor nutritional status; depressed (leukocyte count <5000/mm³ or platelet count <100,000/mm³) bone marrow function; potentially serious infections

The U.S. Food and Drug Administration (FDA) currently recommends that procedures for proper handling and disposal of antineoplastic agents be considered.

Use with caution in patients who have had high-dose pelvic radiation or previous use of alkylating agents. Patient should be hospitalized during initial course of therapy.

Use of floxuridine with pentostatin has been associated with a high incidence of fatal pulmonary toxicity; this combination is not recommended.

Floxuridine preparation should be performed in a Class II laminar flow biologic safety cabinet. Personnel should be wearing surgical gloves and a closed front surgical gown with knit cuffs. Appropriate safety equipment is recommended for preparation, administration, and disposal of antineoplastics. If floxuridine contacts the skin, wash and flush thoroughly with water.

>10%: Gastrointestinal: GI hemorrhage, stomatitis, esophagopharyngitis, diarrhea, gastritis

1% to 10%:

Dermatologic: Dermatitis, rash, alopecia

Gastrointestinal: Anorexia, glossitis

Patients may experience impaired immune response to vaccines

Possible infection after administration of live vaccines in patients receiving immunosuppressants

Mechanism of action and pharmacokinetics are very similar to 5-FU; FUDR® is the deoxyribonucleotide of 5-FU. Inhibits DNA and RNA synthesis via formation of carbonium ions; cross-links strands of DNA, causing an imbalance of growth and cell death

Adults (refer to individual protocols):

I.V.: 0.5-1 mg/kg/day for 6-15 days

May cause drowsiness

May rarely cause agranulocytosis; use caution with clozapine and carbamazepine

No information available to require special

No effects or complications reported

This drug can only be administered by infusion. Follow instructions of prescriber for care of implantable pump. During therapy, do not use alcohol, aspirin-containing products, and OTC medications without consulting prescriber. It is important to maintain adequate nutrition and hydration (2-3 L/day of fluids unless instructed to restrict fluid intake) during therapy; frequent small meals may help. You may experience mild nausea or vomiting (frequent small meals, frequent mouth care, sucking lozenges, or chewing gum may help); you may experience loss of hair (reversible); you will be more susceptible to infection (avoid crowds and exposure to infection as much as possible). Yogurt or buttermilk may help reduce diarrhea. Frequent mouth care and use of a soft toothbrush or cotton swabs may help prevent mouth sores. This drug may cause sterility or birth defects. Increased emotional or physical stress will adversely affect the response to this medication. Notify prescriber if you are experiencing unusual or elevated levels of stress. Report extreme fatigue, pain or numbness in extremities, severe GI upset or diarrhea, bleeding or bruising, fever, chills, sore throat, vaginal discharge, or signs of fluid retention (eg, swelling extremities, difficulty breathing, unusual weight gain). Pregnancy/breast-feeding precautions: Do not get pregnant; use appropriate barrier contraceptive measures. Do not breast-feed while on this drug and for several weeks after last dose. Male: Use barrier contraceptive measures when having intercourse with women of childbearing age. Do not breast-feed.

Infused for intra-arterial use, use infusion pump, either external or implanted

Stability: Reconstituted solutions are stable for up to 14 days (refrigerated); FUDR® is stable in D₅W or normal saline

Injection, preservative free: 100 mg/mL (5 mL)

Powder for injection: 500 mg (5 mL, 10 mL)